Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.46
- Piotroski Score 4.00
- Grade Buy
- Symbol (TSHA)
- Company Taysha Gene Therapies, Inc.
- Price $1.25
- Changes Percentage (-6.72%)
- Change -$0.09
- Day Low $1.19
- Day High $1.36
- Year High $4.32
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.50
- High Stock Price Target $44.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.78
- Trailing P/E Ratio -5.06
- Forward P/E Ratio -5.06
- P/E Growth -5.06
- Net Income $-111,566,000
Income Statement
Quarterly
Annual
Latest News of TSHA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds?
A list of the 10 Most Promising Biotech Stocks was compiled, analyzing Taysha Gene Therapies, Inc. against others. The biotech sector experienced fluctuations due to FDA trials, COVID-19 vaccines, and...
By Yahoo! Finance | 2 weeks ago -
Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?
An article compiled a list of top NASDAQ stocks under $5, with Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ranking 7th....
By Yahoo! Finance | 1 month ago -
Nike forecasts surprise revenue fall as upstarts steal marketshare; stock dives
By Ananya Mariam Rajesh and Juveria Tabassum(Reuters) -Nike on Thursday forecast a surprise drop in fiscal 2025 revenue, hurt by faltering demand for its sneakers as consumers covet newer brands such ...
By Reuters | 4 months ago
